{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:22:37Z","timestamp":1786112557002,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice projected to affect 12.1 million individuals by the year 2030. Patients who are diagnosed with AF have an increased risk of morbidity and mortality. Although catheter ablation is a class I treatment recommendation in patients with symptomatic paroxysmal AF, antiarrhythmic medications (AAM) continue to be the mainstay of treatment in limited resource settings not offering ablation procedures. Currently, the most used AAMs are those which block either the sodium or potassium channels. We hypothesized that the use of selective dual AAM (sodium and potassium channel blockers) (DAAM) improves the chance of maintaining sinus rhythm and decreases the need for catheter ablation when compared with single AAM (SAAM). This retrospective observational study was conducted in 150 patients with paroxysmal AF over 5 years at Richmond University Medical Center in Staten Island, New York. The following data were collected: age, sex, comorbidities, electrocardiogram findings, ejection fraction by echocardiography, classes of AAM, duration, and response to treatments. The primary endpoint included the absence of symptoms and maintenance of sinus rhythm. The secondary endpoint included the requirement of electrical cardioversion or catheter ablation. A total of 86 patients met the inclusion criteria in our analysis. The average age of the patients was 71.06 years (SD = 7.66). About 45 patients were given DAAM of either amiodarone + flecainide or dronedarone + flecainide and were treated for an average of 15.4 months, followed by catheter ablation, if needed. Also, 41 patients received a SAAM followed by catheter ablation, if needed. A Mann\u2013Whitney test indicated that electrical cardioversion and catheter ablation were greater for the SAAM group (Md = 1) than for the DAAM group (Md = 0) (U = 294.00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt;0.001; U = 507.00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt;0.001, respectively). No pro-arrhythmic side effects or death were encountered in either group. Treatment of paroxysmal AF with DAAM is effective compared with SAAM and is less likely to need catheter ablation or electrical cardioversion. Well-designed prospective studies are needed to further explore the use of DAAM in the management of paroxysmal AF and its clinical impact in limited resource settings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000738","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T09:41:50Z","timestamp":1718271710000},"page":"457-461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["New Perspectives in The Management of Paroxysmal Atrial Fibrillation: Dual AntiArrhythmic Medications"],"prefix":"10.1097","volume":"34","author":[{"given":"Safa","family":"Al-Jammali","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Hermann Healthcare System, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Al-Zakhari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas Medical Branch, Galveston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Umesh","family":"Mahtani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Richmond University Medical Center\/Mount Sinai, Staten Island, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Isber","sequence":"additional","affiliation":[{"name":"Department of Electrophysiology, Richmond University Medical Center\/Mount Sinai, Staten Island, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","article-title":"The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.","volume":"114","author":"Andrade","year":"2014","journal-title":"Circ Res"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population.","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12916-022-02533-8","article-title":"Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation.","volume":"20","author":"\u021aica","year":"2022","journal-title":"BMC Med"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/europace\/euac020","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.","volume":"24","author":"Gorog","year":"2022","journal-title":"Europace"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN international collaboration.","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"key":"R6-20260805","article-title":"Embolic ST-elevation myocardial infarction in atrial fibrillation: report of two cases and review of literature.","volume":"14","author":"Doodnauth","year":"2022","journal-title":"Cureus"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1161\/STROKEAHA.121.034777","article-title":"Atrial fibrillation detected after stroke and transient ischemic attack: a novel clinical concept challenging current views.","volume":"53","author":"Sposato","year":"2022","journal-title":"Stroke"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review.","volume":"79","author":"Camm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.293.21.2634","article-title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.","volume":"293","author":"Wazni","year":"2005","journal-title":"JAMA"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"e210247","DOI":"10.1001\/jamanetworkopen.2021.0247","article-title":"Racial\/ethnic and socioeconomic disparities in management of incident paroxysmal atrial fibrillation.","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.","volume":"342","author":"Roy","year":"2000","journal-title":"N Engl J Med"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jama.2009.2029","article-title":"Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.","volume":"303","author":"Wilber","year":"2010","journal-title":"JAMA"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2012.11.064","article-title":"Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation.","volume":"61","author":"Packer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation.","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamacardio.2021.0852","article-title":"Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials.","volume":"6","author":"Turagam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1253\/circj.CJ-08-0608","article-title":"Optimal treatment strategy for patients with paroxysmal atrial fibrillation J-RHYTHM Study.","volume":"73","author":"Ogawa","year":"2009","journal-title":"Circ J"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/HCQ.0000000000000011","article-title":"Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF).","volume":"7","author":"Ha","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial.","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:15:41Z","timestamp":1785942941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000738","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}